UY39724A - Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a - Google Patents

Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a

Info

Publication number
UY39724A
UY39724A UY0001039724A UY39724A UY39724A UY 39724 A UY39724 A UY 39724A UY 0001039724 A UY0001039724 A UY 0001039724A UY 39724 A UY39724 A UY 39724A UY 39724 A UY39724 A UY 39724A
Authority
UY
Uruguay
Prior art keywords
combination
antibody against
treating
malignant neoplasm
prolgolimab
Prior art date
Application number
UY0001039724A
Other languages
English (en)
Inventor
Dmitry Valentinovich Morozov
Mariia Stanislavovna Shustova
Sergei Nikolaevich Fogt
Fedor Borisovich Kryukov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021109765A external-priority patent/RU2787457C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of UY39724A publication Critical patent/UY39724A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso del anticuerpo contra PD-1, en particular prolgolimab, en combinación con al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino, para tratar una neoplasia maligna, y al uso del anticuerpo contra PD-1 prolgolimab en combinación con el anticuerpo contra VEGF, en particular bevacizumab, y al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino, para tratar una neoplasia maligna.
UY0001039724A 2021-04-08 2022-04-08 Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a UY39724A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021109765A RU2787457C2 (ru) 2021-04-08 Способ лечения злокачественного новообразования с использованием комбинации антитела к pd-1 и химиотерапевтического агента

Publications (1)

Publication Number Publication Date
UY39724A true UY39724A (es) 2022-10-31

Family

ID=83546621

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039724A UY39724A (es) 2021-04-08 2022-04-08 Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a

Country Status (12)

Country Link
EP (1) EP4319736A1 (es)
CN (1) CN117500493A (es)
AR (1) AR125322A1 (es)
BR (1) BR112023020856A2 (es)
CL (1) CL2023003012A1 (es)
CO (1) CO2023013510A2 (es)
EC (1) ECSP23076237A (es)
MA (1) MA62924A1 (es)
MX (1) MX2023011952A (es)
TW (1) TW202304511A (es)
UY (1) UY39724A (es)
WO (1) WO2022216184A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070119745A (ko) * 2005-05-12 2007-12-20 화이자 인코포레이티드 수니티닙 말레이트를 사용하는 항암 병행 요법
WO2020226986A2 (en) * 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody

Also Published As

Publication number Publication date
CL2023003012A1 (es) 2024-04-12
WO2022216184A1 (en) 2022-10-13
AR125322A1 (es) 2023-07-05
MX2023011952A (es) 2023-11-09
BR112023020856A2 (pt) 2024-02-06
CO2023013510A2 (es) 2023-11-10
MA62924A1 (fr) 2024-03-29
EP4319736A1 (en) 2024-02-14
ECSP23076237A (es) 2024-01-31
TW202304511A (zh) 2023-02-01
CN117500493A (zh) 2024-02-02

Similar Documents

Publication Publication Date Title
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
CO2017002081A2 (es) Terapia adjuntiva con 25-hidroxi vitamina d
UA116095C2 (uk) Застосування пертузумабу, трастузумабу і хіміотерапії на основі карбоплатину для неоад'ювантного лікування her2-позитивного раку молочної залози ранньої стадії у пацієнта
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
PH12016500839A1 (en) Combination theraphy of an anti cd20 antibody with a btk inhibitor
CO2021006869A2 (es) Anticuerpos humanizados contra c-kit
PE20180454A1 (es) Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2
UY38360A (es) Métodos de tratamiento del cáncer
PE20060461A1 (es) Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
UY39724A (es) Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a
CL2023000741A1 (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos.
CL2017002275A1 (es) Cepas bacterianas productoras de histamina y su uso en el cáncer
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
DOP2023000230A (es) Anticuerpo biespecífico anti–cldn4/anti–cd137
MX2021014486A (es) Complejo de la toxina tipo a de clostridium botulinum, formulacion y uso del mismo.
BR112023021913A2 (pt) Tratamento de câncer com inibidor de raf
MX2021001606A (es) Tratamiento de la malignidades de las celulas b.
BR112023004830A2 (pt) Métodos para tratamento de mieloma múltiplo
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
AR116897A1 (es) Métodos para tratar el cáncer con una combinación de un anticuerpo anti-vegf y un conjugado anticuerpo-fármaco anti-factor tisular
WO2016196373A8 (en) Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof